Liraglutide reduces liver fat but not liver stiffness in 197 MASLD patients over 6 months | Research

The takeaway

In 197 MASLD patients, liraglutide significantly reduced hepatic steatosis (CAP -26 dB/m at 2 months), BMI (30.9→28.9), and insulin resistance over 6 months, but did not significantly improve liver stiffness.

Fat reduced, stiffness unchanged
Liraglutide reduced liver fat significantly within 2 months but did not improve liver stiffness—an important distinction for MASLD management expectations

What the researchers found

CAP (liver fat): -26.0 dB/m at 2 months (p significant). Liver stiffness: no significant change. BMI: 30.9→28.9 (p<0.001). HOMA-IR improved. MASLD criteria prevalence declined. 197 patients, 6-month follow-up.

Why it matters

Distinguishing between fat reduction and fibrosis improvement is critical—while liraglutide reduces liver fat, the lack of stiffness improvement suggests it may not reverse established fibrosis. This has implications for treatment expectations.

How the study worked

Retrospective cohort of 197 MASLD patients (2020-2023). VCTE (FibroScan) at baseline, 2 and 6 months. Metabolic parameter tracking.

What this study cannot tell us

Retrospective. Significant dropout (197→142 at 6 months). VCTE has limitations for fibrosis assessment. No control group. Short follow-up for fibrosis changes.

How to read the evidence

Retrospective cohort with objective VCTE measurements. Good real-world evidence but lacks control group.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs clearly reduce hepatic steatosis, but their impact on fibrosis—the stage that determines liver-related mortality—remains uncertain. This study adds nuance to the MASLD treatment narrative.

Questions still open

Would longer treatment duration improve liver stiffness?
Are semaglutide or tirzepatide more effective at reducing fibrosis?
Should MASLD patients on liraglutide expect fat reduction but not fibrosis reversal?

Common questions

Does liraglutide help fatty liver disease?

It significantly reduces liver fat—measurable within 2 months by FibroScan. However, it did not improve liver stiffness (a marker of scarring/fibrosis) in this 6-month study. So liraglutide helps the fat component but may not reverse established liver damage.

Is reducing liver fat enough?

Reducing fat is important because it slows further liver damage and improves metabolic health. However, liver fibrosis (scarring) is what ultimately leads to cirrhosis and liver failure. Patients with significant fibrosis may need additional or different treatments beyond GLP-1 drugs.

Read the original research

The Impact of Liraglutide on Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal of gastroenterology and hepatology, 40(12), 2976-2986

View on PubMed ↗Publisher’s paper ↗

Citation

So, Jae Eun; Jeong, Jaehong; Hong, Jung Pyo; Kim, Dong Yun; Lee, Jae Seung; Kim, Mi Na; Kim, Beom Kyung; Park, Jun Yong; Kim, Do Young; Lee, Hye Won; Kim, Seung Up. (2025). The Impact of Liraglutide on Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.. Journal of gastroenterology and hepatology, 40(12), 2976-2986. https://doi.org/10.1111/jgh.70134